ArticleBMC cancer2025
Nasopharyngeal carcinoma in sub-Saharan Africa: clinicopathological profiles, patterns of care, and survival outcomes of patients treated at a leading radiotherapy center.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum lactate dehydrogenase and vascular endothelial growth factor A level as a predictor of treatment response in locally advanced-stage World Health Organisation type 3 nasopharyngeal carcinoma.Contemporary oncology (Poznan, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn sub-Saharan Africa, the clinicopathological features, management strategies, and survival outcomes of nasopharyngeal carcinoma (NPC) remain underreported, posing challenges to improving patient care and treatment outcomes. The aim of the study was to evaluate the clinicopathological profiles, patterns of care, and survival of patients with NPC treated with curative intent at a major radiotherapy center in sub-Saharan Africa.
methodsThis retrospective cohort study analyzed 83 patients with histopathologically confirmed NPC treated over a 10-year period. Data on demographics, clinical features, management, and treatment outcomes were extracted from patients' medical records. Statistical analyses were conducted using SPSS, with a significance threshold of p < 0.05. Survival analysis was performed using Kaplan-Meier curves, whilst associations between clinicopathological variables& survival were assessed using Cox proportional hazard models.
resultsThe mean age was 32.8 ± 18.3 years whilst the male-to-female ratio was 2.3:1. In all, 8.4% had EBV-positive NPC, whilst 9.6% were tobacco smokers. Most participants (94%) had a good performance status. Overall, 38.6%, 26.5%, and 20.5% were diagnosed with stages IVB, IVA and III NPC respectively. In all, 75.9% received definitive chemo-radiation without either induction or adjuvant chemotherapy. A total of 78.3% were treated to a standard radiotherapy dose of 70 Gy in 35 fractions delivered over 7 weeks, whilst other patients were treated to lower doses of 68 Gy in 34 fractions (10.8%), 66 Gy in 33 fractions (4.8%) or 64 Gy in 32 fractions to meet critical organ constraints. There were low acute (25.3%) and long-term (15.7%) treatment-induced toxicity rates. The 1-, 3- and 5-year disease-free survival rates were 75%, 45%, and 25%, respectively whereas overall survival rates at the same time points were 90%, 65%, and 35%, respectively.
conclusionAdvanced-stage diagnosis remains a major challenge due to delayed detection and limited healthcare access. While Linac-based radiotherapy, including IMRT, is increasingly used, chemotherapy remains underutilized, raising concerns about treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.